Crizotinib

Red

Brand Name(s):Xalkori

Indication:Lung cancer non-small cell(NSCLC) Advanced

Rationale:1,2,3

Considered:Sep-12

Review Date:Jan-22

Comments:
NICE TA 422
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Dec 16
…………………………
Drug Safety Update
Crizotinib (Xalkori): risk of cardiac failure – full details at:https://www.gov.uk/drug-safety-update/crizotinib-xalkori-risk-of-cardiac-failure
November 2015